| Date | Title | Description |
| 26.03.2024 | Dementia Discovery Fund Look Ahead: 2024 is shaping up to be another big year in the fight against dementia | As we approach the second quarter of 2024, the SV Health Investors Partners investing out of the Dementia Discovery Fund (DDF) have summarised the key themes and topics that are likely to be front and centre over the next nine months:
1. St... |
| 16.03.2022 | Swapping out the brain’s cleanup crew treats neurological disease in mice, study shows | From anemia to leukemia, unhealthy cells can make for unhealthy people, but replacing these cells can help patients. What if the same were true for some of the world’s most devastating neurological diseases?
A new study published Wednesday ... |
| 24.03.2020 | Alector Announces the Appointment of Paula Hammond, Ph.D., to the Board of Directors | March 23, 2020 at 8:30 AM EDT |
| 30.04.2019 | After amyloid failures, it’s time to take a new tack for treating Alzheimer’s | If insanity is doing the same thing over and over again but expecting different results, then the last decade or so of Alzheimer’s disease drug development has been insane. Three carefully designed, well-executed, and fully resourced trials... |
| 07.02.2019 | DDF Notes Alector's $176 million U.S. initial public offering | London, [7 February] 2019 - The Dementia Discovery Fund (“DDF”), a venture capital fund focused on discovering and developing novel therapies for dementia, welcomes the news that Alector, a clinical stage biopharmaceutical company pioneerin... |
| 27.07.2018 | Biotech Company Alector Raises $133M in Series E Financing | Alector, a South Francisco, CA-based biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, closed a $133m Series E financing.
Backers included Deerfield Managemen... |
| 25.07.2018 | Alector raises $133 million in Series E round for neurology drug development | The plan is to enter three drug candidates into the early next year, Chief Business Officer Sabah Oney said in a phone interview. These include AL001, being developed for frontotemporal dementia, as well as AL002 and AL003, which respective... |
| 25.07.2018 | Alector raises $133M in 5th VC round to push neuro-immunology drugs into Alzheimer’s trials | Previous Fierce 15 winner Alector has raised $133 million through a fifth round of venture capital financing, with plans to move at least three of its immune-modulating drugs into clinical testing against neurodegenerative disorders within ... |
| 25.07.2018 | Term Sheet — Wednesday, July 25 | 5 Qs WITH A DEALMAKER
Fifth Wall Ventures has a pretty narrow investment thesis. It invests exclusively in startups focused on real estate technology across sectors such as hospitality, retail, and construction.
Paid Content Securing the en... |
| 25.07.2018 | Alector Raises $133M Series E from Deerfield | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alector, a privately held biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, today announced the closing of a $13... |
| 25.07.2018 | DDF notes Alector raises $133 million in Series E Financing | The Dementia Discovery Fund notes that Alector, a privately held biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, has announced the closing of a $133 million... |
| 25.07.2018 | Alector Raises $133M Series E from Polaris Partners | SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Alector, a privately held biotechnology company focused on developing therapies that harness the immune system to cure neurodegenerative diseases and cancer, today announced the closing of a $13... |
| 25.07.2018 |
Amgen Backed Alector Adds $133M
| South San Francisco-based Alector, a biotechnology company focused on finding treatments for neurodegenerative diseases and cancer, announced Wednesday that it has raised $133M in a Series E funding round. The company--which is backed by Th... |
| 31.03.2016 | New insight into Alzheimer’s suggests potential path to treatment | An immune process implicated earlier this year in schizophrenia may also cause the devastating brain damage of Alzheimer’s disease, a surprising convergence that suggests the body’s defense system is responsible for two of the cruelest brai... |
| 07.01.2016 | Alector Announces $29.5M Series D Financing | - |
| 07.01.2016 | Alector Raises $29.5M Series D Fundin |
SAN FRANCISCO, CA, Alector today announced that it has raised $29.5 million in a Series D financing.
>> Click here for more funding data on Alector
>> To export Alector funding data to PDF and Excel, click here
After havi... |
| 07.01.2016 | Alector gets $29.5M for monoclonal antibody approach to Alzheimer’s disease | CEO Arnon Rosenthal told MedCity News of this financing in the fall, saying that Alector’s unique approach to brain diseases is causing a lot of buzz in the life sciences investment community. The round comes largely from the Dementia Disco... |
| 07.01.2016 | Alector Raises $29.5M in Series D Financing | Alector LLC, a San Francisco, CA-based biotech company developing immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, raised $29.5m in a Series D financing.
The round was led by the Dementia Discovery ... |
| 16.09.2015 | Alector Raises $32M in Series C Financing | Alector LLC, a San Francisco, CA-based biotech company advancing immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, raised $32m in Series C financing.
The round was led by MRL Ventures with participat... |
| 16.09.2015 | Alector raises $32M for immunotherapy approach to Alzheimer’s and other neurodegenerative disease | “We are a hypothesis-driven company,” Rosenthal explained in a phone interview with MedCity News.
Alector posits that neurodegeneration is caused, in part, by immune deficiency. Its platform works by enhancing or dialing back certain functi... |
| 16.09.2015 | Alector Raises $32M Series C |
SAN FRANCISCO, CA, Biotech company has raised $32 million in Series C financing.
>> Click here for more funding data on Alector
>> To export Alector funding data to PDF and Excel, click here
Alector LLC, a biotech company... |
| 10.03.2014 | J&J takes an early interest in biotech startup Alector’s approach to Alzheimer’s treatment | That’s a bit of a different approach than some of the so-called disease-modifying therapies that have disappointed in clinical trials over the past few years, including J&J’s own bapineuzumab. With more than 7 million people expected to... |
| 31.10.2013 | Alector Secures Series A Financing |
SAN FRANCISCO, CA, Biotech company dedicated to the discovery and development of novel therapeutics for Alzheimer's disease, other forms of dementia, and mechanistically related neurodegenerative disorders, announced the closing of their ... |
| 31.10.2013 | Alector Closes Series A Financing | Alector LLC, a San Francisco, CA-based biotech company, closed a Series A financing of undisclosed amount.
The round was led by Polaris Venture Partners and OrbiMed Advisors. In conjunction with the funding, General Partner Terry McGuire (P... |
| - | Alector raises $32M for immunotherapy approach to Alzheimer’s and other neurodegenerative disease | San Francisco immunotherapy startup Alector just raised $32 million in a Series C round to build out a monoclonal antibody approach to neurodegenerative disease.
Alector is backed by some top-notch venture capital: This round comes from MRL... |
| - | J&J takes an early interest in biotech startup Alector’s approach to Alzheimer’s treatment | In another move to potentially beef up its Alzheimer’s pipeline, Johnson & Johnson has struck a drug development deal with one of the companies located at its innovation lab in San Francisco.
J&J’s Innovation Center and San Francisc... |
| - | Alector gets $29.5M for monoclonal antibody approach to Alzheimer’s disease | San Francisco-based biotech Alector just brought in yet another chunk of cash to fund its monoclonal antibody approach to Alzheimer’s disease and other neurodegenerative conditions.
Right on the heels of a September Series C round of $32 mi... |
| - | Alector raises $133 million in Series E round for neurology drug development | A company seeking to use an approach similar to immuno-oncology for treating neurodegenerative disease has closed its fifth round of private funding.
South San Francisco, California-based Alector said Wednesday that it had raised $133 milli... |
